| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:12759095 | IVR | 1700 mg/L | 1700 mg/L | Affects ovulation | Reproductive endocrine-mediated perturbations |
| IVR | 1700 mg/L | 1700 mg/L | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| PMID:17066414 | IVR | 75 mg/L | - | No significant effects observed | - |
| IVR | 250 mg/L | - | No significant effects observed | - | |
| IVR | 600 mg/L | 600 mg/L | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/L | 600 mg/L | Decreased placental weights | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/L | 600 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 600 mg/L | 600 mg/L | Affects skeletal development | Developmental endocrine-mediated perturbations | |
| PMID:31310931 | IVTH | 0.000001 M | 0.000001 M | Alters estrogen-responsive genes | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000000001 M | 0.000000001 M | Alters estrogen-responsive genes | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Alters estrogen-responsive genes | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000001 M | 0.00000001 M | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000001 M | 0.00000001 M | Alters estrogen-responsive genes | Reproductive endocrine-mediated perturbations | |
| PMID:7251397 | IVR | 400 mg/L | - | No significant effects observed | - |
| IVR | 200 mg/L | 200 mg/L | Reduced acetylcholinesterase activity | Neurological endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Increased serotonin (5-HT) levels | Neurological endocrine-mediated perturbations | |
| IVR | 800 mg/L | 800 mg/L | Reduced acetylcholinesterase activity | Neurological endocrine-mediated perturbations | |
| PMID:8427017 | IVR | 320 mg/kg | 320 mg/kg | Affects locomotor activity | Neurological endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Affects locomotor activity | Neurological endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.